FIGURE 4.

Ex vivo perfusion of pig lungs. Humanized vWF (h*pvWF, red) were compared to reference lungs with pvWF (blue), with base regimen (solid; n = 5 h*pvWF, n = 5 pvWF), or additional treatment (dashed; n = 5 h*pvWF, n = 5 pvWF). (A) Survival was similar for both groups regardless of treatment, with most experiments reaching elective termination at 480 min (p = .44). (B) There was significant improvement in platelet sequestration in the humanized vWF lungs, compared to reference lungs with pvWF, regardless of treatment (p ≤ .01). The reduction in platelet sequestration in the h*pvWF lungs was both rapidly significant (5 min) and sustained (8 h), regardless of treatment. (C) Platelet activation as demonstrated by platelet expression of P-selectin (CD62P) was significantly attenuated in human blood perfusing h*pvWF lungs, compared to pvWF lungs at 6 h, regardless of treatment (p < .001). (D) There was no difference in rise in plasma beta thromboglobulin levels (βTG), regardless of genetics or treatment. Error bars represent standard error of the mean.

* base regimen, † treated *p < .05, **p < .01, ***p < .001, ****p < .0001